Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - acitretin, quantity: 10 mg - capsule, hard - excipient ingredients: titanium dioxide; purified water; sodium lauryl sulfate; iron oxide red; gelatin; maltodextrin; microcrystalline cellulose; sodium ascorbate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of:,? severe intractable psoriasis in all its forms,? severe forms of disorders of keratinisation such as,- hyperkeratosis palmaris et plantaris,- pustulosis palmaris et plantaris,- ichthyosis,- keratosis follicularis (darier's disease),- lichen planus affecting the skin or the mucosae,- pityriasis rubra pilaris

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - acitretin, quantity: 25 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; purified water; iron oxide red; sodium ascorbate; iron oxide yellow; gelatin; maltodextrin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of:,? severe intractable psoriasis in all its forms,? severe forms of disorders of keratinisation such as,- hyperkeratosis palmaris et plantaris,- pustulosis palmaris et plantaris,- ichthyosis,- keratosis follicularis (darier's disease),- lichen planus affecting the skin or the mucosae,- pityriasis rubra pilaris

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 5 mg - capsule, soft - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); glycerol; purified water; butylated hydroxyanisole; hydrogenated vegetable oil; titanium dioxide; disodium edetate; soya oil; dl-alpha-tocopherol; gelatin; yellow beeswax; partially hydrogenated soya oil - treatment of patients with severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 40 mg - capsule, soft - excipient ingredients: titanium dioxide; glycerol; sorbitol solution (70 per cent) (non-crystallising); hydrogenated soya oil; dl-alpha-tocopherol; soya oil; disodium edetate; butylated hydroxyanisole; sunset yellow fcf; gelatin; partially hydrogenated soya oil; yellow beeswax; purified water - oratane is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cyctic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: gelatin; soya oil; sorbitol solution (70 per cent) (non-crystallising); yellow beeswax; brilliant scarlet 4r; dl-alpha-tocopherol; disodium edetate; purified water; glycerol; butylated hydroxyanisole; iron oxide black; titanium dioxide; partially hydrogenated soya oil; hydrogenated vegetable oil - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: purified water; indigo carmine; gelatin; disodium edetate; partially hydrogenated soya oil; butylated hydroxyanisole; dl-alpha-tocopherol; sorbitol solution (70 per cent) (non-crystallising); glycerol; yellow beeswax; brilliant scarlet 4r; soya oil; titanium dioxide; hydrogenated vegetable oil - oratane is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 30 mg - capsule, soft - excipient ingredients: soya oil; disodium edetate; partially hydrogenated soya oil; hydrogenated soya oil; yellow beeswax; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; titanium dioxide; iron oxide red; butylated hydroxyanisole; dl-alpha-tocopherol - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 30 mg - capsule, soft - excipient ingredients: soya oil; disodium edetate; partially hydrogenated soya oil; hydrogenated soya oil; yellow beeswax; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; titanium dioxide; iron oxide red; butylated hydroxyanisole; dl-alpha-tocopherol - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas bean (australia) pty ltd - 34867 - bedpan, general-purpose - a reusable device used by bedridden patients as a rcepticle for urine and faeces.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas bean (australia) pty ltd - 40504 - bottle, urine, reusable - a reusable bottle designed to be urinated into by a male.